Work

Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 99KB, Supplementary Methods: The supplemental material contains additional detail on the pharmacokinetic and pharmacodynamic methods used during the study as well as a summary table of safety events and a figure detailing patient disposition. Supplemental Table 1: Summary of safety events in all study cohorts.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361908409
Cites:
Cited by:
Related to: 10